We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

51 hedge funds and large institutions have $99.2M invested in OnKure Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $49M → $99.2M (+$50.2M)

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

84.96% more ownership

Funds ownership: 8.63% → 93.59% (+85%)

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 51 → 51 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
51
Holders Change
–
Holders Change %
0%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
20
Reduced
10
Closed
19
Calls
$243K
Puts
–
Net Calls
+$243K
Net Calls Change
+$140K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$27.8M
2
Citadel Advisors
Citadel Advisors
Florida
+$16.1M
3
PA
Perceptive Advisors
New York
+$15.2M
4
SB
Samsara BioCapital
California
+$12.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$9.36M

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$5.88M
2
OCA
Octagon Capital Advisors
New York
-$3.83M
3
AI
Acuitas Investments
Washington
-$685K
4
Two Sigma Investments
Two Sigma Investments
New York
-$230K
5
JC
JBF Capital
Colorado
-$136K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$15.8M +$27.8M +1,837,739 New
ACA
2
Acorn Capital Advisors
New York
$10.2M +$21.8M +1,439,674 New
Citadel Advisors
3
Citadel Advisors
Florida
$8.78M +$16.1M +1,065,023 +11,463%
PA
4
Perceptive Advisors
New York
$8.64M +$15.2M +1,004,439 New
SB
5
Samsara BioCapital
California
$7.09M +$12.5M +824,155 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$6.08M +$9.36M +618,523 +701%
VPC
7
Vestal Point Capital
New York
$5.46M +$8.4M +555,060 +694%
DTC
8
Deep Track Capital
Connecticut
$4.51M +$7.93M +523,989 New
SG
9
StepStone Group
California
$4.23M +$7.45M +491,938 New
NMC
10
NEA Management Company
Maryland
$4.12M -$15 -1 -0%
HCM
11
Highbridge Capital Management
New York
$3.44M +$1.42M +93,474 +31%
TCM
12
Tang Capital Management
California
$2.53M – – –
CG
13
Carlyle Group
District of Columbia
$2.33M -$15 -1 -0%
IC
14
Ikarian Capital
Texas
$2.18M +$2.29M +151,187 +147%
Bank of America
15
Bank of America
North Carolina
$2.15M +$3.78M +249,521 +206,216%
ACM
16
Altium Capital Management
New York
$1.88M +$3.31M +218,386 New
AAA
17
Affinity Asset Advisors
New York
$1.24M +$2.18M +144,159 New
Millennium Management
18
Millennium Management
New York
$1.24M +$2M +132,042 +1,095%
BlackRock
19
BlackRock
New York
$809K +$1.09M +71,884 +325%
ACM
20
Aisling Capital Management
New York
$762K -$15 -1 -0%
SFM
21
Sphera Funds Management
Israel
$751K +$1.32M +87,354 New
BFM
22
Boothbay Fund Management
New York
$671K +$1.18M +78,021 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$659K +$835K +55,149 +257%
PM
24
Prosight Management
Texas
$548K +$965K +63,754 New
NCM
25
Nantahala Capital Management
Connecticut
$471K -$45 -3 -0%
1
2 3

OKUR Hedge Fund Activity: Q4 2024 in Review

51 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2024, worth a combined $99.2M — up 103% from $49M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new OKUR positions and 19 closed out — a net gain of 1 holder — while 20 added to existing stakes and 10 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $27.8M. The largest seller was BML Capital Management, exiting entirely with an estimated $5.88M sold.

  • 51 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $99.2M of OnKure Therapeutics stock for Q4 2024, up 103% quarter-over-quarter.
  • 20 funds opened new OnKure Therapeutics positions in Q4 2024 and 19 closed out, a net change of +1 holder.
  • The largest OnKure Therapeutics buyer in Q4 2024 was Cormorant Asset Management, an estimated $27.8M added.
  • The largest OnKure Therapeutics seller in Q4 2024 was BML Capital Management, an estimated $5.88M sold.

Based on aggregated 13F filings for Q4 2024.